This biweekly Women’s health video recap highlights regulatory approvals, clinical progress, research collaborations, healthcare access updates, and evolving regulatory initiatives shaping women’s health care.
Dive deeper
In Today’s Newsletter
💊 IBRANCE FDA approval in HR+, HER2+ metastatic breast cancer [1] [US • 24 Jun 2026]
https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-ibrance-regimen-hr-her2-metastatic
Context: Pfizer IBRANCE (palbociclib; CDK4/6 inhibitor) was studied in the Phase 3 PATINA trial after induction treatment.
Key point: FDA approved IBRANCE with trastuzumab, with or without pertuzumab, and endocrine therapy for adult HR+, HER2+ locally advanced or metastatic breast cancer.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Datroway CHMP recommendation in 1st-line metastatic TNBC [2] [EU • 26 Jun 2026]
https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html
Context: AstraZeneca and Daiichi Sankyo Datroway (datopotamab deruxtecan; TROP2-directed ADC) was assessed in TROPION-Breast02.
Key point: CHMP recommended Datroway monotherapy for adult unresectable or metastatic TNBC not eligible for PD-1/PD-L1 inhibitor therapy.
Implication: May influence prescriber choice and payer reviews pending full data.
🎯 Enhertu EU tumour-agnostic HER2-positive solid tumour approval [3] [EU • 29 Jun 2026]
https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-eu-for-her-solid-tumours.html
Context: AstraZeneca and Daiichi Sankyo Enhertu (trastuzumab deruxtecan; HER2-directed ADC) was supported by DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02.
Key point: EU approved Enhertu for adult patients with previously treated unresectable or metastatic HER2-positive (IHC 3+) solid tumours with no satisfactory options.
Implication: May influence prescriber choice and payer reviews pending full data.
🤝 Astex–Genentech breast cancer discovery collaboration [4] [06 Jun 2026]
https://www.otsuka.co.jp/en/company/newsreleases/2026/20260706_1.html
Context: Otsuka subsidiary Astex Pharmaceuticals will use fragment-based drug discovery to target a cell-cycle-dependent regulator in breast cancer.
Key point: Astex granted Genentech an exclusive worldwide licence to compounds from an existing breast cancer drug discovery program.
Implication: Signals pipeline investment and modality expansion.
🏥 NICE backs Keytruda for locally advanced cervical cancer [5] [England • 25 Jun 2026]
https://pharmaphorum.com/news/nice-delivers-more-good-news-cervical-cancer-patients
Context: NICE reviewed MSD Keytruda (pembrolizumab; PD-1 inhibitor) with chemoradiotherapy in stage 3 or 4 locally advanced cervical cancer.
Key point: NICE said Keytruda plus chemoradiotherapy is a frontline NHS option for eligible women in England.
Implication: May influence prescriber choice and payer reviews pending full data.
💊 Ireland proposes pharmacy contraception renewals [6] [Ireland • 30 Jun 2026]
https://www.euractiv.com/news/ireland-plans-to-let-pharmacists-prescribe-contraception/
Context: Ireland’s Health Bill 2026 would let pharmacists renew short-acting contraception prescriptions under clinical protocols.
Key point: Women aged 17 and over could renew eligible contraception at community pharmacies without returning to a GP each time.
Implication: May expand screening, initiation, and follow-up at scale.
👩 EMA expands women’s health regulatory initiatives [7] [EU • 02 Jul 2026]
https://www.ema.europa.eu/en/news/ema-steps-efforts-medicines-womens-health
Context: EMA is launching work on representation in trials, sex-specific labelling, pregnancy and breastfeeding evidence, and real-world evidence.
Key point: EMA will hold a women’s health workshop on 28–29 Sep 2026 to map gaps and priorities.
Implication: May expand screening, initiation, and follow-up at scale.
Why it matters
- Breast cancer updates span regulatory approvals, CHMP review, and discovery-stage partnering.
- ADCs remain central across TNBC, HER2-positive disease, and tumour-agnostic precision oncology.
- Cervical cancer access in England is expanding through NICE immunotherapy recommendations.
- Ireland’s pharmacy proposal could reduce contraception access friction.
- EMA’s women’s health agenda may shape trial design, labelling, and evidence generation in Europe.
📚 View the full Women’s health archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.
FAQ
What did FDA approve for Pfizer IBRANCE?
FDA approved IBRANCE with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for adult HR+, HER2+ locally advanced or metastatic breast cancer after induction treatment. [1]
What is the EU status of Datroway in metastatic TNBC?
CHMP recommended Datroway monotherapy for 1st-line treatment of adult unresectable or metastatic TNBC in patients not eligible for PD-1/PD-L1 inhibitor therapy. [2]
What makes the Enhertu EU approval notable?
Enhertu was approved in the EU as a tumour-agnostic HER2-directed therapy and ADC for previously treated HER2-positive (IHC 3+) metastatic solid tumours with no satisfactory options. [3]
What are Astex and Genentech collaborating on?
Astex and Genentech entered an exclusive worldwide research collaboration and licence agreement for small molecule candidates targeting a cell-cycle-dependent regulator in breast cancer. [4]
Who could access Keytruda under the NICE cervical cancer guidance?
NICE backed Keytruda with chemoradiotherapy as a frontline option for women with stage 3 or 4 locally advanced cervical cancer that has not metastasised distantly. [5]
What is EMA doing on women’s health medicines?
EMA is mapping gaps across women’s health, including clinical trial representation, sex-specific assessment and labelling, pregnancy and breastfeeding evidence, and real-world evidence. [7]
Entities / Keywords
Pfizer IBRANCE, palbociclib, CDK4/6 inhibitor, HR+ breast cancer, HER2+ breast cancer, metastatic breast cancer, PATINA
AstraZeneca, Daiichi Sankyo, Datroway, datopotamab deruxtecan, TROP2 ADC, TNBC, TROPION-Breast02, CHMP, EMA
Enhertu, trastuzumab deruxtecan, HER2-directed ADC, HER2-positive solid tumours, tumour-agnostic therapy, DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02
Otsuka, Astex Pharmaceuticals, Genentech, Roche, breast cancer, fragment-based drug discovery, small molecule inhibitors
NICE, MSD, Keytruda, pembrolizumab, chemoradiotherapy, cervical cancer, locally advanced cervical cancer, NHS England
Ireland, pharmacists, contraception prescriptions, Free Contraception Scheme, community pharmacy
EMA, women’s health, CTIS, pregnancy, breastfeeding, DARWIN EU, real-world evidence, clinical trials
References
- https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-ibrance-regimen-hr-her2-metastatic
- https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html
- https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-eu-for-her-solid-tumours.html
- https://www.otsuka.co.jp/en/company/newsreleases/2026/20260706_1.html
- https://pharmaphorum.com/news/nice-delivers-more-good-news-cervical-cancer-patients
- https://www.euractiv.com/news/ireland-plans-to-let-pharmacists-prescribe-contraception/
- https://www.ema.europa.eu/en/news/ema-steps-efforts-medicines-womens-health